Compare Citius Pharmaceuticals Inc (CTXR) vs Lululemon Athletica Inc (LULU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Lululemon Athletica Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.54 (market cap $14.64M), while Lululemon Athletica Inc trades at $119.83 (market cap $13.32B). The key difference: Lululemon Athletica Inc is far larger — about 909.8× Citius Pharmaceuticals Inc's market cap, and Lululemon Athletica Inc is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | LULU | |
|---|---|---|
Market Cap | $14.64M | $13.32B |
Sector | Health | Consumer Cyclical |
52-Week High | $1.82 | $233.31 |
52-Week Low | $0.53 | $105.43 |
Enterprise Value | $10.86M | $13.94B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
Lululemon (LULU) trades at $120.30, up 0.87% today, showing resilience amid a challenging year. The stock has beaten earnings estimates for three consecutive quarters, with Q2 2026 results pending. Fundamentals remain strong with a 17.13% net margin and 32.03% ROE in 2025, though revenue growth is moderating. Technical indicators signal a bullish bias, with the current price near pivot point support at $121. Recent news highlights board stability after a proxy settlement but also ongoing brand controversies.
The outlook is cautiously optimistic. Valuation appears attractive with a P/E of 9.74, below sector averages, and a consensus price target of $130.53 implies upside. Key risks include North American sales weakness, intense competition, and potential brand damage from recent controversies. Earnings execution and international expansion are critical for a sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Lululemon Athletica Inc
Lululemon Athletica Inc. designs, distributes, and markets athletic apparel, footwear, and accessories for women, men, and girls. Lululemon offers pants, shorts, tops, and jackets for both leisure and athletic activities such as yoga and running. The company also sells fitness accessories, such as bags, yoga mats, and equipment. Lululemon sells its products through more than 600 company-owned stores in 18 countries, e-commerce, outlets, and wholesale accounts. The company was founded in 1998 and is based in Vancouver, Canada.
Read more on LULU →
